Generate QR code
Open Access
Subscription Access
Arrhythmogenic cardiomyopathy as a complication of tachysystolic atrial fibrillation
https://doi.org/10.30629/0023-2149-2025-103-8-9-670-676
Abstract
The article presents a clinical case of a diagnostically difficult disease – arrhythmogenic cardiomyopathy in a patient with paroxysmal atrial fibrillation. The complexity of this diagnosis is due to the fact that it can only be made retrospectively, when after successful rhythm control, including cardioversion or ablation, the systolic function of the left ventricle is restored and clinical symptoms disappear. The issues of the prevalence of the disease and its place in the modern classification of cardiomyopathies are considered. The features of structural, functional and hemodynamic changes in the heart are noted. Modern approaches to the diagnosis of the disease and the choice of an effective treatment strategy are discussed.
About the Authors
T. V. Zawalishina
Central Clinical Hospital with Outpatient Clinic of Department of Presidential Affairs
Россия
Россия
Tatyana V. Zawalishina — doctor of functional diagnostics
Moscow
M. G. Matveeva
Central Clinical Hospital with Outpatient Clinic of Department of Presidential Affairs
Россия
Россия
Marina G. Matveeva — Candidate of Medical Sciences, doctor of functional diagnostics
Moscow
N. V. Lomakin
Central Clinical Hospital with Outpatient Clinic of Department of Presidential Affairs
Россия
Россия
Nikita V. Lomakin — Doctor of Medical Sciences, Professor, head of Cardiology Department №2
Moscow
M. N. Alekhin
Central Clinical Hospital with Outpatient Clinic of Department of Presidential Affairs
Россия
Россия
Mikhail N. Alekhin — Doctor of Medical Sciences, Professor, functional diagnostics
Moscow
References
1. Van Gelder I.C., Rienstra M., Bunting, K.V., Casado-Arroyo R., Caso V., Crijns H.J.G.M.et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2024;45(36):3314–3414. http://doi:10.1093/eurheartj/ehae176
2. Arakelyan M.G., Bokeria L.A., Vasilyeva E.Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V. et al. Atrial fibrillation and flutter. Clinical guidelines 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russian). DOI: 10.15829/1560-4071-2021-4594
3. Ulus T., Okyay K., Kabul HK. et al. Turkish Society of Cardiology consensus paper on management of arrhythmia-induced cardiomyopathy. Anatol. J. Cardiol. 2019;21(2):98–106. DOI: 10.14744/AnatolJCardiol.2019.60687
4. Huizar J.F., Ellenbogen K.A., Tan A.Y., Kaszala K. ArrhythmiaInduced Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2019;73(18):2328–2344. DOI: 10.1016/j.jacc.2019.02.045
5. Soliman E.Z., Safford M.M., Muntner P., Khodneva Y., Dawood F.Z., Zakai N.A.et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 2014;174(1):107–14. DOI: 10.1001/jamainternmed.2013.11912
6. Qin D., Mansour M.C., Ruskin J.N., Heist E.K. Atrial fibrillationmediated cardiomyopathy. Circ. Arrhythm. Electrophysiol. 2019;12(12):e007809. DOI: 10.1161/CIRCEP.119.007809
7. Raymond-Paquin A., Nattel S., Wakili R., Tadros R. Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy. Can. J. Cardiol. 2018;34(11):1449–1460. DOI: 10.1016/j.cjca.2018.07.475
8. González-Ferrero T., Bergonti M., López-Canoa J.N., Arias F.G., Eiras Penas S., Spera F.et al. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study. ESC Heart Fail. 2023;10(5):3055–3066. DOI: 10.1002/ehf2.14448
9. Serban T., Badertscher P., du Fay de Lavallaz J. et al. Definition and management of arrhythmia-induced cardiomyopathy: findings from the European Heart Rhythm Association survey. Europace. 2024;26(5):euae112. DOI: 10.1093/europace/euae112
10. Towbin J.A., McKenna W.J., Abrams D.J. et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019;16(11):e373–e407. DOI: 10.1016/j.hrthm.2019.09.019
11. Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., BarrialesVilla R. et al., ESC Scientific Document Group (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023;44(37):3503–3626. DOI: 10.1093/eurheartj/ehad194
12. Eda Y., Nabeta T., Iikura S., Takigami Y., Fujita T., Iida Y. et al. Nondilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes. ESC Heart Fail. 2024;11(3):1463– 1471. DOI: 10.1002/ehf2.14711
13. Khan M.N., Jaïs P., Cummings J., Di Biase L., Sanders P., Martin D.O. et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med. 2008;359:1778–1785. DOI: 10.1056/NEJMoa0708234
14. Prabhu S., Taylor A.J., Costello B.T., Kaye D.M., McLellan A. J.A.et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI Study. Journal of the American College of Cardiology. 2017;70(16):1949–1961. DOI: 10.1016/j.jacc.2017.08.041
15. Pandey A., Kim S., Moore C., Thomas L., Gersh B., Allen L.A. et al. ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail. 2017;5:44–52. DOI: 10.1016/j.jchf.2016.09.016
16. Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A.et al., ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262
17. Gentl esk P.J., Sauer W.H., Gerstenfeld E.P., Lin D., Dixit S., Zado E., Callans D., Marchlinski F.E. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2007;18:9–14. DOI: 10.1111/j.1540-8167.2006.00653.x
18. Nakano Y., Ochi H., Sairaku A., Onohara Y., Tokuyama T., Motoda C. et al. HCN4 Gene Polymorphisms Are Associated With Occurrence of Tachycardia-Induced Cardiomyopathy in Patients With Atrial Fibrillation. Circ. Genom Precis. Med. 2018;11(7):e001980. DOI: 10.1161/CIRCGEN.117.001980
19. Deshmukh P.M., Krishnamani R., Romanyshyn M., Johnson A.K., Noti J.D. Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. International journal of molecular medicine. 2004;13(3):455–458. DOI: 10.3892/ijmm.13.3.455
20. Gopinathannair R., Etheridge S.P., Marchlinski F.E., Spinale F.G., Lakkireddy D., Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J. Am. Coll. Cardiol. 2015;66(15):1714–1728. DOI: 10.1016/j.jacc.2015.08.038
21. Shantsila E., Shantsila A., Blann A.D., Lip G.Y. Am. J. Cardiol. 2013;111:996–1001. DOI: 10.1016/j.amjcard.2012.12.005
22. Korthals D., Eckardt L. The new European Society of Cardiology guideline for the management of cardiomyopathies: key messages for cardiac electrophysiologists. Herzschrittmacherther Elektrophysiol. 2023;34(4):311–323. DOI: 10.1007/s00399-023-00975-y
23. Goette A., Kalman J.M., Aguinaga L., Akar J., Cabrera J.A., Chen S.A. et al. Document Reviewers: (2016). EHRA/HRS/APHRS/ SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. Europace. 2016;18(10):1455–1490. DOI: 10.1093/europace/euw161
24. Nia A.M., Gassanov N., Dahlem K.M., Caglayan E., Hellmich M., Erdmann E., Er F. Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin. Res. Cardiol. 2011;100:887–896. DOI: 10.1007/s00392-011-0319-y
25. Di Biase L., Mohanty P., Mohanty S., et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133(17):1637–1644. DOI: 10.1161/CIRCULATIONAHA.115.019406
26. Marrouche N. F., Brachmann J., Andresen D., Siebels J., Boersma L., Jordaens L.et al. CASTLE-AF Investigators (2018). Catheter ablation for atrial fibrillation with heart failure. The New England journal of medicine. 2018;378(5):417–427. DOI: 10.1056/NEJMoa1707855
27. Watanabe H., Okamura K., Chinushi M., Furushima H., Tanabe Y., Kodama M., Aizawa Y. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. International heart journal. 2008;49(1):9–47. DOI: 10.1536/ihj.49.39
28. Ju W., Yang B., Li M., Zhang F., Chen H., Gu K. et al. Tachycardiomyopathy complicated by focal atrial tachycardia: incidence, risk factors, and long-term outcome. J. Cardiovasc. Electrophysiol. 2014;25(9):953–957. DOI: 10.1111/jce.12428
29. Ling L.H., Kalman J.M., Ellims A.H., Iles L.M., Medi C., Sherratt C.et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ. Arrhythm. Electrophysiol. 2013;6(4):697–704. DOI: 10.1161/CIRCEP.113.000681
Review
For citations:
Zawalishina T.V., Matveeva M.G., Lomakin N.V., Alekhin M.N. Arrhythmogenic cardiomyopathy as a complication of tachysystolic atrial fibrillation. Clinical Medicine (Russian Journal). 2025;103(8-9):670-676. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-8-9-670-676
Views:
26
JATS XML
Email this article 